Education
About Us
Working with TipRanks
Follow Us
Haemonetics Corp. (HAE)
NYSE:HAE
Earnings Data
Report Date
May 07, 2026Before Open (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
1.27Last Year’s EPS
1.24Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported durable organic growth (notably in plasma and blood management technologies), margin expansion, accelerating cash generation, and raised guidance for revenue and free cash flow. These positives outweigh the clear near-term challenges in Interventional Technologies (driven by PFA adoption, OEM dynamics and order timing), vascular closure share loss in select accounts, and the lingering reported revenue impact from prior portfolio transitions. Management outlined funded remediation plans for IVT (MVP XL label expansion and PercuSeal Elite launch) and expects IVT to return to growth in FY2027, supporting a positive outlook.Company Guidance
Solid revenue and organic growth
Q3 revenue of $339M and year-to-date revenue of $988M; organic revenue growth ex CSL of 8% in the quarter and 10% year-to-date (management notes reported results include a $153M impact from prior-year portfolio transitions).
Earnings per share growth and raised EPS outlook
Adjusted EPS of $1.31 in the quarter (up 10% year-over-year) and $3.67 year-to-date (up 11%); updated full-year adjusted EPS guidance of $4.90 to $5.00 per share.
Plasma franchise acceleration
Plasma revenue of $139M in the quarter (reported growth +3%); organic plasma growth ex CSL of 20% in the quarter and 22% year-to-date; U.S. plasma collections grew in the low double digits in Q3; management raised full-year plasma organic guidance ex CSL to 17%–19% (from 14%–17%).
Margin expansion across the P&L
Adjusted gross margin 60.2% in Q3 (+250 basis points YoY) and 60.5% year-to-date (+390 basis points YoY); adjusted operating margin expanded to 26.3% in Q3 (+60 bps YoY) and to 25.7% year-to-date (+200 bps YoY); company expects full-year adjusted operating margin ~26%–27%.
Strong free cash flow conversion and upgraded cash guidance
Q3 free cash flow $74M, year-to-date FCF $165M, operating cash flow $94M in Q3 and $222M year-to-date; FCF conversion 121% of adjusted net income in Q3 and 95% year-to-date; raising FY26 free cash flow guidance to $200M–$220M (from $170M–$210M) and expect FCF conversion to exceed 80%.
Outsized growth in blood management technologies (Nexus/TEG)
Blood management technologies revenue up 8% in the quarter and 11% year-to-date driven by Nexus/Persona adoption, TEG 6s disposable sales, and adoption of the heparinase neutralization cartridge; management highlights runway to upgrade legacy TEG systems and increase utilization.
Improved company revenue guidance
Company raised full-year reported revenue guidance to a decline of 1%–3% (from prior 1%–4%) and raised organic revenue guidance ex CSL to 8%–10% (midpoint up ~50 bps).
Strategic capital deployment and tuck-in acquisition
Management repurchased ~360,000 shares for $25M late in the quarter, previously repurchased $75M, and completed a $61M acquisition (VIVUSHORE / PercuSeal Elite) to strengthen interventional technologies; cash on hand $363M (up 18% since start of fiscal year).
HAE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HAE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 05, 2026 | $65.95 | $65.02 | -1.41% |
Nov 06, 2025 | $50.72 | $67.11 | +32.31% |
Aug 07, 2025 | $75.77 | $55.63 | -26.58% |
May 08, 2025 | $64.25 | $68.01 | +5.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Haemonetics Corp. (HAE) report earnings?
Haemonetics Corp. (HAE) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).
What is Haemonetics Corp. (HAE) earnings time?
Haemonetics Corp. (HAE) earnings time is at May 07, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HAE EPS forecast?
HAE EPS forecast for the fiscal quarter 2026 (Q4) is 1.27.